Is Your Paper Ready for Journal of Hematology & Oncology? How Editors Actually Decide

What this journal is

Journal of Hematology & Oncology (JHO) is a BioMed Central open-access journal specializing in hematologic malignancies and solid tumors. It publishes ~1,000 papers annually, making it high-volume but still selective. IF 5.8 is strong for an open-access oncology journal.

Editorial focus: mechanistic understanding of cancer biology plus clinical translation. Papers are expected to have one or the other, ideally both. Purely bioinformatic analysis of public databases is less favored than wet-lab validation.

The numbers that matter

Impact Factor: 5.8 (2024 JCR). Stable. Good for oncology researchers.

Acceptance Rate: ~30%. Higher than Cell Reports (20-25%) or Molecular Systems Biology (12-15%) but lower than PLOS ONE (40%). Moderate selectivity.

APC: $1,800. Lower than Cell Reports ($4,800), eLife (free), or PLOS Biology ($2,000). Good value for open-access publication at this impact level.

Desk Rejection: ~25% of submissions. Reasonable. You have a 75% chance of external review.

Time to decision: 4-8 weeks average. Fast for oncology journals.

What works at JHO

Mechanism-driven studies (What's the biology?); studies with clinical or translational relevance (Does this matter for patients?); well-designed preclinical or clinical trials with appropriate sample sizes; combination approach studies (drug + target validation + patient data, for example); reproducible, detailed methods.

What gets desk-rejected

Purely descriptive gene expression profiling without functional follow-up; single anecdotal case reports; bioinformatic studies relying entirely on public data without validation; incremental drug screening results without mechanism; papers where claims significantly exceed evidence.

Reviewer priorities

Scientific rigor (proper controls, adequate sample sizes, clear statistics); novelty for the oncology/hematology field (not necessarily genome-wide novel); mechanistic clarity; clinical or translational relevance; reproducibility and transparency.

Should you submit there?

Yes, if: your work is oncology or hematology focused; you combine mechanism with clinical/translational insight; you have solid experimental rigor; you want faster review than Nature Communications (10-12 weeks vs JHO 4-8); open-access benefits matter for your field reach.

Consider elsewhere if: your work is pure clinical epidemiology (Clinical Cancer Research might be better); work is early-stage preclinical without mechanism; primarily computational (PLOS Computational Biology better suited).

Decision cue

Can you answer both "what is the mechanism?" and "why does this matter clinically?" If both answers are solid, JHO is receptive. If only one, you have a decent chance; if neither, consider more specialized journals.